|
|
|
|
|
|
Sponsored by: |
Schering-Plough |
Information provided by: | Schering-Plough |
ClinicalTrials.gov Identifier: | NCT00551213 |
The purpose of this study is to determine the activity of SCH 717454 in patients with relapsed or recurrent colorectal cancer.
Condition | Intervention | Phase |
Colorectal Cancer |
Drug: SCH 717454 Drug: Chemotherapy and SCH 717454 |
Phase II |
MedlinePlus related topics: | Cancer Colorectal Cancer |
ChemIDplus related topics: | Insulin-like growth factor I Mecasermin rinfabate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A Fixed-Sequence, Open-Label Study to Determine the Activity of SCH 717454 as Assessed by Positron Emission Tomography in Subjects With Relapsed or Recurrent Colorectal Cancer |
Estimated Enrollment: | 59 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
SCH 717454: Experimental
SCH 717454
|
Drug: SCH 717454
SCH 717454 will be administered intravenously once every two weeks until disease progression.
|
Chemotherapy followed by SCH 717454.: Active Comparator
Chemotherapy followed by SCH 717454
|
Drug: Chemotherapy and SCH 717454
One cycle of chemotherapy currently approved and available on the market for use in colorectal cancer followed by SCH 717454.
|
It will be a randomized, fixed-sequence, open-label study in patients with diagnosis of relapsed or recurrent colorectal cancer to assess response, duration of response, safety and tolerability of SCH 717454.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: SP Clinical Trial Registry Call Center | 1-888-772-8734 |
United States, California | |||||
Investigational Site 6 | Recruiting | ||||
Los Angeles, California, United States, 90033 | |||||
Investigational Site 12 | Recruiting | ||||
Palm Springs, California, United States, 92262 | |||||
United States, Florida | |||||
Investigational Site 8 | Recruiting | ||||
Jacksonville, Florida, United States, 32256 | |||||
United States, Georgia | |||||
Investigational Site 1 | Recruiting | ||||
Atlanta, Georgia, United States, 30341 | |||||
United States, Illinois | |||||
Investigational Site 3 | Recruiting | ||||
Chicago, Illinois, United States, 60637 | |||||
Investigational Site 13 | Recruiting | ||||
Peoria, Illinois, United States, 61615 | |||||
United States, Washington | |||||
Investigational Site 7 | Recruiting | ||||
Seattle, Washington, United States, 98109 | |||||
Canada | |||||
Investigational Site 5 | Recruiting | ||||
London, Canada, N6A 4L6 | |||||
Investigational Site 11 | Recruiting | ||||
Montreal, Canada, H2L 4M1 | |||||
Investigational Site 9 | Recruiting | ||||
Toronto, Canada, M5G 2M9 | |||||
Investigational Site 10 | Recruiting | ||||
Montreal, Canada, H3A 1A1 |
Schering-Plough |
Study Director: | Brian D Lu, MD, PhD | Schering-Plough |
Responsible Party: | Schering-Plough ( Susan Arbuck, MD - Vice President, Global Clinical Research, Oncology ) |
Study ID Numbers: | P04721 |
First Received: | October 29, 2007 |
Last Updated: | September 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00551213 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|